LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Home・Aktien・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Geschlossen

BrancheGesundheitswesen

32.73 5.38

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

30.86

Max

32.76

Schlüsselkennzahlen
By Trading Economics
Einkommen	-2.5M 14M
Verkäufe	-12M 194M
KGV Branchendurchschnitt	15.427 49.888
EPS	1.76
Gewinnspanne	7.491
Angestellte	423
EBITDA	-216M 88M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+71.93% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-90M 1B
Vorheriger Eröffnungskurs	27.35
Vorheriger Schlusskurs	32.73

Nachrichtenstimmung

By Acuity

50%

155 / 344 Ranking in Healthcare

Collegium Pharmaceutical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Juni 2026, 21:51 UTC

Wichtige Markttreiber

Merlin Shares Rally After Defense Department's Design Review Wraps

4. Juni 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4. Juni 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4. Juni 2026, 23:42 UTC

Akquisitionen, Fusionen, Übernahmen

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4. Juni 2026, 23:41 UTC

Akquisitionen, Fusionen, Übernahmen

Energy Resources of Australia to Enter Trading Halt

4. Juni 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4. Juni 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Juni 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4. Juni 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Juni 2026, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4. Juni 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4. Juni 2026, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4. Juni 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4. Juni 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4. Juni 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4. Juni 2026, 18:47 UTC

Akquisitionen, Fusionen, Übernahmen

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4. Juni 2026, 18:38 UTC

Ergebnisse

Money Quote: Tech Weakness in Context -- WSJ

4. Juni 2026, 18:24 UTC

Ergebnisse

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4. Juni 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4. Juni 2026, 16:58 UTC

Ergebnisse

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4. Juni 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4. Juni 2026, 16:38 UTC

Ergebnisse

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Juni 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4. Juni 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4. Juni 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4. Juni 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer-Vergleich

Kursveränderung

Collegium Pharmaceutical Inc Prognose

Kursziel

By TipRanks

71.93% Vorteil

12-Monats-Prognose

Durchschnitt 53.4 USD 71.93%

Hoch 60 USD

Tief 44 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Collegium Pharmaceutical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Collegium Pharmaceutical Inc – Dist abgegeben haben.

Stimmung

By Acuity

155 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.